I jumped back into SVA today . H1N1 seems to be causing more issues (thus more press) in China after it seemed to have settled down. With over 10 million doses ordered by the Chinese government and winning the contract to make the common flu vaccine SVA earnings are going to be very attractive and their name is going to become more and more common bring in more investors. With only around 45 million outstanding shares they are an attractive stock in light of everything. They will be transfering from the NYSE to NASDAQ on or around Nov 16th.



LinkBack URL
About LinkBacks
Reply With Quote

